COX-2和iNOS在16例非小细胞肺癌组织中的表达及临床意义  

Expressions and Significance of COX-2 and INOS in 16 Patients with Non-Small-Cell Lung Carcinoma

作　　者：张菁华[1] 刘晓萍[1] 

机构地区：[1]青岛大学医学院组胚教研室,山东青岛266021

出　　处：《肿瘤基础与临床》2011年第6期489-491,共3页journal of basic and clinical oncology

摘　　要：目的研究诱导型环氧化酶(COX-2)和诱导型一氧化氮合酶(iNOS)在非小细胞肺癌(NSCLC)组织中的表达及临床意义。方法采用免疫组织化学方法检测16例NSCLC(腺癌和鳞癌各8例)组织及相应配对的16例癌旁正常组织中COX-2和iNOS表达。结果 NSCLC组织中COX-2阳性率为50.0%,iNOS阳性率为37.5%。COX-2表达与患者病理类型、TNM分期和淋巴结转移有关,但与性别及年龄无关。iNOS表达与患者TNM分期有关,与性别、年龄、病理类型及淋巴结转移均无关。结论 COX-2和iNOS在肺癌的发生和发展中具有重要作用。Objective To investigate the expressions and significance of inducible cyclooxygenase-2 （COX-2） and inducible nitric oxide synthase （iNOS） in non-small-cell lung carcinoma （NSCLC）. Methods Immunohistochemistry was used to detect COX-2 and iNOS expressions in 16 cases of NSCLC （ the 8 cases of adenocarcinoma,the 8 cases of squamous cell carcinoma） and 16 cases of corresponding adjacent normal tissues. Results In the NSCLC, the COX-2 positive expression rate was 50.0%, and that of iNOS was 37.5%. COX-2 expression was correlated with pathological type, TNM stage and lymph node metastasis, but was not correlated with gender, age;iNOS expression was related with TNM stage, but was not related with gender, age, pathological type, and lymph node metastasis. Conclusion COX-2 and iNOS can play the important role in the development and progression of NSCLC.

关 键 词：环氧化酶-2 诱导型一氧化氮合酶 非小细胞肺癌 免疫组织化学 

分 类 号：R734.2[医药卫生—肿瘤]